WO2020127990A1 - Système de production de compositions pharmaceutiques à base de crispr - Google Patents

Système de production de compositions pharmaceutiques à base de crispr Download PDF

Info

Publication number
WO2020127990A1
WO2020127990A1 PCT/EP2019/086708 EP2019086708W WO2020127990A1 WO 2020127990 A1 WO2020127990 A1 WO 2020127990A1 EP 2019086708 W EP2019086708 W EP 2019086708W WO 2020127990 A1 WO2020127990 A1 WO 2020127990A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
rna
pathogen
protein
patient
Prior art date
Application number
PCT/EP2019/086708
Other languages
English (en)
Inventor
Theodore Anastasius PRAMER
Martin Ekenberg
Corinne Kay
Original Assignee
Biomedrex Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedrex Ab filed Critical Biomedrex Ab
Publication of WO2020127990A1 publication Critical patent/WO2020127990A1/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search

Abstract

L'invention concerne un système comprenant au moins un dispositif de séquençage et au moins un dispositif de synthèse d'ARN, le dispositif de séquençage comprenant un premier ordinateur et le dispositif de synthèse de nucléotides comprenant un second ordinateur, le dispositif de séquençage étant conçu pour a) recevoir au moins un échantillon biologique comprenant du matériel génétique se présentant sous la forme de polynucléotides, b) déterminer la séquence polynucléotidique du matériel génétique et la stocker sous la forme de données de séquence, c) fournir les données de séquence au dispositif de synthèse d'ARN; le dispositif de synthèse d'ARN étant conçu pour recevoir les données de séquence, le dispositif de séquençage ou le dispositif de synthèse d'ARN étant conçus pour stocker les données de séquence sous la forme d'un ensemble de données de séquence de patient représentant le génome du patient et d'un ensemble de données de séquence d'agent pathogène représentant au moins une partie du matériel génétique de l'agent pathogène, le dispositif de synthèse d'ARN étant conçu pour : d) trouver, dans l'ensemble de données de séquence d'agent pathogène, au moins une séquence polynucléotidique cible de 18 à 60 nucléotides de long, ladite séquence cible n'étant pas présente dans l'ensemble de données de séquence génétique du patient, e) synthétiser un brin antisens d'ARN pour une protéine de type CRISPR qui est complémentaire de la séquence cible de l'étape e), le brin antisens d'ARN comprenant en outre une séquence « poignée » prédéterminée qui médie la liaison à une protéine de type CRISPR.
PCT/EP2019/086708 2018-12-20 2019-12-20 Système de production de compositions pharmaceutiques à base de crispr WO2020127990A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1851634-4 2018-12-20
SE1851634 2018-12-20

Publications (1)

Publication Number Publication Date
WO2020127990A1 true WO2020127990A1 (fr) 2020-06-25

Family

ID=69156392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/086708 WO2020127990A1 (fr) 2018-12-20 2019-12-20 Système de production de compositions pharmaceutiques à base de crispr

Country Status (1)

Country Link
WO (1) WO2020127990A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
WO2003064026A1 (fr) 2002-01-31 2003-08-07 Nimblegen Systems Llc Substrat predessine, dispositif et procede pour la synthese optique de sondes d'adn
WO2012012779A2 (fr) 2010-07-23 2012-01-26 Beckman Coulter Inc. Système et procédé comprenant des unités analytiques
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
US8454972B2 (en) 2004-07-16 2013-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
US20160350476A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Antiviral methods and compositions
US20180169658A1 (en) 2016-12-21 2018-06-21 Quandx Inc. Systems and methods for molecular diagnostics

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
WO2003064026A1 (fr) 2002-01-31 2003-08-07 Nimblegen Systems Llc Substrat predessine, dispositif et procede pour la synthese optique de sondes d'adn
US8454972B2 (en) 2004-07-16 2013-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
WO2012012779A2 (fr) 2010-07-23 2012-01-26 Beckman Coulter Inc. Système et procédé comprenant des unités analytiques
US20160350476A1 (en) * 2015-05-29 2016-12-01 Agenovir Corporation Antiviral methods and compositions
US20180169658A1 (en) 2016-12-21 2018-06-21 Quandx Inc. Systems and methods for molecular diagnostics

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ABUDAYYEH ET AL., NATURE, vol. 550, 2017, pages 280 - 284
BERND ZETSCHE ET AL: "Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System", CELL, vol. 163, no. 3, 1 October 2015 (2015-10-01), AMSTERDAM, NL, pages 759 - 771, XP055553375, ISSN: 0092-8674, DOI: 10.1016/j.cell.2015.09.038 *
COXGOOTENBERGABUDAYYEH ET AL., SCIENCE, 2017
DE BUHR HENDRIK ET AL: "Harnessing CRISPR to combat human viral infections", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 54, 26 July 2018 (2018-07-26), pages 123 - 129, XP085510271, ISSN: 0952-7915, DOI: 10.1016/J.COI.2018.06.002 *
DUO PENG ET AL: "EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens", MICROBIAL GENOMICS, vol. 1, no. 4, 13 October 2015 (2015-10-13), XP055681566, DOI: 10.1099/mgen.0.000033 *
FREIJE ET AL., MOLECULAR CELL, vol. 76, 2019, pages 826 - 837
GLASSLEELIXU, TRENDS IN BIOTECHNOLOGY, 2017
LEE ET AL., NATURE BIOMEDICAL ENGINEERING, vol. 1, 2017, pages 889 - 901
LI ET AL., BIOMATERIALS, vol. 178, 2018, pages 652 - 662
LIUZHANGLIUCHENG, JOURNAL OF CONTROLLED DISEASE, vol. 266, 2017, pages 17 - 26
MALI ET AL., SCIENCE, vol. 339, 2013, pages 823 - 826
MOUT ET AL., ACS NANO, vol. 11, 2017, pages 2452 - 2458
PARK ET AL., NATURE COMMUNICATIONS, vol. 9, 2018, pages 3313
SMARGONCOXPYZOCHA ET AL., MOLECULAR CELL, 2017
UEDA, MICROBIOLOGY AND IMMUNOLOGY, vol. 60, no. 7, July 2016 (2016-07-01), pages 483 - 496
WANG ET AL., PNAS, vol. 113, no. 11, 15 March 2016 (2016-03-15), pages 2868 - 2873
ZETSCHE ET AL., CELL, vol. 163, 2015, pages 759 - 771

Similar Documents

Publication Publication Date Title
AU2016299271B2 (en) A system, device and a method for providing a therapy or a cure for cancer and other pathological states
JP6968416B2 (ja) Ｒｎａ誘導性の、ｈｉｖ感染の処置のための、方法および組成物
US10689691B2 (en) Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
US20230287373A1 (en) Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US10988777B2 (en) Method for inducing CCR5Δ32 deletion by using CRISPR-Cas9 genome editing technique
Hu et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection
US20190367910A1 (en) Methods and compositions for rna-guided treatment of hiv infection
JP2020188757A (ja) Ｈｉｖ感染のｒｎａガイド処置のための方法および組成物
US20180057810A1 (en) Functional screening with optimized functional crispr-cas systems
US20210395812A1 (en) Method for detecting off-target effect of adenine base editor system based on whole-genome sequencing and use thereof in gene editing
US20160355795A1 (en) Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
KR20160097327A (ko) 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
JP2018500913A (ja) マイクロ流体送達による遺伝子編集
CN107949424A (zh) Tat诱导的基于crispr/核酸内切酶的基因编辑
US20130143204A1 (en) Determination of in vivo dna double-strand break localization and application thereof
WO2022132765A1 (fr) Inactivation biallélique de b2m
WO2022132756A1 (fr) Inactivation biallélique de trac
Shmakova et al. CRISPR/Cas: History and perspectives
Morshedzadeh et al. An update on the application of CRISPR technology in clinical practice
Ebrahimi et al. CRISPR-Cas technology as a revolutionary genome editing tool: mechanisms and biomedical applications
WO2020127990A1 (fr) Système de production de compositions pharmaceutiques à base de crispr
Han et al. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs
WO2020169705A1 (fr) Thérapie à base de virus
Ab Halim et al. Clustered Regularly Interspaced Short Palindromic Repeat Paired Associated Protein 9 (CRISPR-Cas9) System and Its Opportunity in Medical Science-A Narrative Review
WO2024064607A2 (fr) Inactivation biallélique de tet2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19835295

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19835295

Country of ref document: EP

Kind code of ref document: A1